AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21081579 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 43
Study 21081579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 43
Study 21081579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 43
Study 21081579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Examination
Number of subjects: 43
Study 19153121 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/cisplatin (XP)
Number of subjects: 316
Study 19153121 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/cisplatin (FP)
Number of subjects: 316
Study 18180581 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment methods for cartilage defects, specific interventions not detailed, timing and methods of treatment unclear.
Number of subjects: 0
Study 18180581 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic evaluation for diagnosis, considered the gold standard.
Number of subjects: 0
Study 18180581 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural course of cartilage defects, treatment methods not specified.
Number of subjects: 0
Study 14753327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer in De‐Re‐ solutions
Number of subjects: 24
Study 14753327 — intervention group
Group type: COMPARATOR
Intervention: Other materials in H2O and AS
Number of subjects: 24
Study 11340534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with clarithromycin, trimethoprim and sulfamethoxazole, or both
Number of subjects: 394
Study 11340534 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 394
Study 9273875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/m3 zinc oxide
Number of subjects: 13
Study 9273875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/m3 zinc oxide
Number of subjects: 13
Study 9273875 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 13
Study 7958542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 1.75 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 3.5 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 7.0 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: COMPARATOR
Intervention: AG 1.0 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: COMPARATOR
Intervention: AG 2.0 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: COMPARATOR
Intervention: AG 4.0 mg
Number of subjects: 9
Study 7958542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (all doses)
Number of subjects: 9
Study 7958542 — intervention group
Group type: COMPARATOR
Intervention: AG (all doses)
Number of subjects: 9
Study 7958542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 9
Study 2885301 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, 80 mg twice daily)
Number of subjects: 28
Study 2885301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN, 100 mg once a day)
Number of subjects: 28
Study 2885301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 28
Study 31685489 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic bariatric surgery (MBS)
Number of subjects: 93
Study 31685489 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (metformin alone or in combination with rosiglitazone or intensive lifestyle intervention)
Number of subjects: 93
Study 31062044 — intervention group
Group type: EXPERIMENTAL
Intervention: Knotless cinch-bridge technique
Number of subjects: 37
Study 31062044 — intervention group
Group type: COMPARATOR
Intervention: Suture-bridge technique
Number of subjects: 37
Study 31062044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 37
Study 28454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound-guided PCI with the novel everolimus-eluting platinum-chromium Synergy stent followed by 4 months of dual antiplatelet therapy (DAPT)
Number of subjects: 818
Study 28454794 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting cobalt-chromium Xience stent followed by 12 months of DAPT
Number of subjects: 818
Study 25352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) testing
Number of subjects: 13480
Study 25352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) co-infection
Number of subjects: 13480
Study 25352691 — intervention group
Group type: EXPERIMENTAL
Intervention: All three infections (CT, NG, TV)
Number of subjects: 13480
Study 25352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfection positivity
Number of subjects: 13480
Study 25352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichomonas vaginalis (TV) association with other infections
Number of subjects: 13480
Study 23576210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 60
Study 23576210 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTA)
Number of subjects: 60
Study 22314719 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetotherapeutic device (MTD) applied externally to the site of pain (maximum magnetic flux density, 55 +/- 5 mT; length, 500 mm; diameter, 4.5 mm)
Number of subjects: 62
Study 22314719 — intervention group
Group type: COMPARATOR
Intervention: Non-MTD (sham control, 0 mT; 500 mm; diameter, 4.5 mm)
Number of subjects: 62
Study 19154471 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0
Study 19154471 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib
Number of subjects: 0
Study 19154471 — intervention group
Group type: EXPERIMENTAL
Intervention: temsirolimus
Number of subjects: 0
Study 19154471 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (in combination with interferon)
Number of subjects: 0
Study 19154471 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 0
Study 17537090 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (including progressive endurance and resistance training)
Number of subjects: 66
Study 17537090 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (attention control)
Number of subjects: 66
Study 15130715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback training
Number of subjects: 27
Study 15130715 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance training
Number of subjects: 27
Study 11676993 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients performing a bicycle incremental test
Number of subjects: 11
Study 11676993 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients during exercise
Number of subjects: 11
Study 11676993 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 11
Study 9648079 — intervention group
Group type: EXPERIMENTAL
Intervention: Free pentosidine
Number of subjects: 134
Study 9648079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin
Number of subjects: 134
Study 9648079 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline increases in free pentosidine and neopterin
Number of subjects: 134
Study 9648079 — intervention group
Group type: COMPARATOR
Intervention: Protein-bound pentosidine
Number of subjects: 134
Study 9648079 — intervention group
Group type: COMPARATOR
Intervention: IL-6 and CRP
Number of subjects: 134
Study 8129059 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% return air (index phase)
Number of subjects: 75
Study 8129059 — intervention group
Group type: COMPARATOR
Intervention: 0% return air (reference phase)
Number of subjects: 75
Study 2510284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (single oral dose)
Number of subjects: 0
Study 2510284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (repeated evening doses)
Number of subjects: 0
Study 796739 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone therapy
Number of subjects: 53
Study 796739 — intervention group
Group type: COMPARATOR
Intervention: Daily prednisone
Number of subjects: 53
Study 31930358 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men (CBIM) program
Number of subjects: 973
Study 31381157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride test toothpaste
Number of subjects: 0
Study 31381157 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate‐based control
Number of subjects: 0
Study 31381157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of 0.454% stannous fluoride test toothpaste
Number of subjects: 0
Study 28035910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical unilateral anterior-posterior mobilisation
Number of subjects: 32
Study 28035910 — intervention group
Group type: COMPARATOR
Intervention: Placebo cervical unilateral A-P light touch pressure
Number of subjects: 32
Study 26150444 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents.
Number of subjects: 420
Study 26150444 — intervention group
Group type: COMPARATOR
Intervention: CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) administered weekly for 6 weeks.
Number of subjects: 420
Study 26150444 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after CCRT.
Number of subjects: 420
Study 26150444 — intervention group
Group type: COMPARATOR
Intervention: CCRT with docetaxel and cisplatin (DP).
Number of subjects: 420
Study 24662902 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty group (knee replacement)
Number of subjects: 62
Study 24662902 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 62
Study 21672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 597
Study 21672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 597
Study 21672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 597
Study 21672123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study 21672123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 597
Study 18279865 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-mm diameter 4-way angulation endoscope (XGIF-XP240N2, Olympus)
Number of subjects: 291
Study 18279865 — intervention group
Group type: COMPARATOR
Intervention: 5.2-mm diameter 2-way angulation endoscope (GIF-N260, Olympus)
Number of subjects: 291
Study 16818537 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic aspiration
Number of subjects: 58
Study 16818537 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 58
Study 12767952 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat (T & T) strategy for Helicobacter pylori (HP), n = 321
Number of subjects: 650
Study 12767952 — intervention group
Group type: COMPARATOR
Intervention: Usual care, n = 329
Number of subjects: 650
Study 11147379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg/kg) administered IV
Number of subjects: 38
Study 11147379 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 38
Study 9499585 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk participants
Number of subjects: 50
Study 9499585 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study 8224303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal trabeculectomy
Number of subjects: 60
Study 8224303 — intervention group
Group type: COMPARATOR
Intervention: Superior trabeculectomy
Number of subjects: 60
Study 8224303 — intervention group
Group type: COMPARATOR
Intervention: Temporal trabeculectomy
Number of subjects: 60
Study 3531953 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin subcutaneously daily for 28 days
Number of subjects: 40
Study 3531953 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution (placebo) administered daily for 28 days
Number of subjects: 40
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year in SLS I
Number of subjects: 300
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo in SLS II
Number of subjects: 300
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of mycophenolate mofetil in SLS II
Number of subjects: 300
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) over 2 years
Number of subjects: 300
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline skin score and older age
Number of subjects: 300
Study 30409830 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term changes in surrogate measures of SSc-ILD progression
Number of subjects: 300
Study 29750475 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86
Study 29750475 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 86
Study 29750475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 26890095 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 16
Study 26890095 — intervention group
Group type: COMPARATOR
Intervention: Sham tRNS
Number of subjects: 16
Study 24951020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (60 mg/kg)
Number of subjects: 63
Study 24951020 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate (10 mL/kg)
Number of subjects: 63
Study 24951020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63
Study 22252356 — intervention group
Group type: EXPERIMENTAL
Intervention: ID diet (1,200 mg/hen per day)
Number of subjects: 240
Study 22252356 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL diet (1,010 mg/hen per day)
Number of subjects: 240
Study 22252356 — intervention group
Group type: EXPERIMENTAL
Intervention: SP diet (600 mg/hen per day)
Number of subjects: 240
Study 22252356 — intervention group
Group type: COMPARATOR
Intervention: ID diet (1,010 mg/hen per day)
Number of subjects: 240
Study 22252356 — intervention group
Group type: EXPERIMENTAL
Intervention: IDL diet (1,200 mg/hen per day)
Number of subjects: 240
Study 20139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotics
Number of subjects: 309
Study 20139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical delayed antibiotics (by 48 hours)
Number of subjects: 309
Study 20139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on high symptom score
Number of subjects: 309
Study 20139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on dipstick results
Number of subjects: 309
Study 20139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics based on midstream urine analysis
Number of subjects: 309
Study 20139218 — intervention group
Group type: COMPARATOR
Intervention: Immediate antibiotics
Number of subjects: 309
Study 17703389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpancreatic septotomy
Number of subjects: 306
Study 17703389 — intervention group
Group type: COMPARATOR
Intervention: Needle‐knife sphincterotomy
Number of subjects: 306
Study 17703389 — intervention group
Group type: COMPARATOR
Intervention: Conventional pull‐type sphincterotomy
Number of subjects: 306
Study 15477510 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 0
Study 15477510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11181283 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 27
Study 9693578 — intervention group
Group type: EXPERIMENTAL
Intervention: Total occlusal reduction
Number of subjects: 117
Study 9693578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated occlusal reduction (nonfunctional cusp reduction)
Number of subjects: 117
Study 9693578 — intervention group
Group type: COMPARATOR
Intervention: Control (occlusion untouched)
Number of subjects: 117
Study 8169337 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg twice daily
Number of subjects: 50
Study 8169337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3045351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (gum) used ad lib for smoking urges or on a fixed schedule (12 pieces per day)
Number of subjects: 600
Study 3045351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (gum) used on a fixed schedule (12 pieces per day)
Number of subjects: 600
Study 3045351 — intervention group
Group type: COMPARATOR
Intervention: Placebo and no gum groups
Number of subjects: 600
Study 31816096 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 78
Study 31816096 — intervention group
Group type: COMPARATOR
Intervention: Microscopic approach
Number of subjects: 78
Study 29490102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavior change intervention (BCI)
Number of subjects: 457
Study 29490102 — intervention group
Group type: COMPARATOR
Intervention: Nonintensive control group
Number of subjects: 457
Study 28689785 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administration
Number of subjects: 134
Study 28689785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 134
Study 26329694 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage and mental training (n=19)
Number of subjects: 93
Study 26329694 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (n=19)
Number of subjects: 93
Study 26329694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental training (n=19)
Number of subjects: 93
Study 26329694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause (n=19)
Number of subjects: 93
Study 26329694 — intervention group
Group type: COMPARATOR
Intervention: Control (n=17)
Number of subjects: 93
Study 24276838 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (MgSO4) 100 mg/kg every 8 hours
Number of subjects: 104
Study 24276838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 24276838 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (MgSO4)
Number of subjects: 104
Study 21689707 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 0
Study 21689707 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 18343748 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g once daily for 3 days
Number of subjects: 267
Study 18343748 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg twice daily for 7 days
Number of subjects: 267
Study 16580659 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI measured on the DPC Immulite
Number of subjects: 213
Study 16580659 — intervention group
Group type: COMPARATOR
Intervention: cTnT measured on Elecsys 1010
Number of subjects: 213
Study 14712970 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg ginger extract (EV.EXT35; equivalent to 1.5 g of dried ginger) given four times per day for 4 days
Number of subjects: 120
Study 14712970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11095428 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term fasting (2.5-day)
Number of subjects: 8
Study 9218089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg 30 min before meals)
Number of subjects: 11
Study 9218089 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg 60 min before meals)
Number of subjects: 11
Study 8475148 — intervention group
Group type: EXPERIMENTAL
Intervention: Large‐celled alternating pressure mattresses
Number of subjects: 0
Study 8475148 — intervention group
Group type: COMPARATOR
Intervention: Small‐celled mattresses
Number of subjects: 0
Study 3892679 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg omeprazole
Number of subjects: 12
Study 3892679 — intervention group
Group type: EXPERIMENTAL
Intervention: 60mg omeprazole
Number of subjects: 12
Study 3892679 — intervention group
Group type: COMPARATOR
Intervention: Control (no omeprazole)
Number of subjects: 12
Study 30919005 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.057 mg/kg)
Number of subjects: 28
Study 30919005 — intervention group
Group type: COMPARATOR
Intervention: Placebo haloperidol
Number of subjects: 28
Study 29627268 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention using specific lexical formulations ('do you have 'any' vs. 'some' other concerns?')
Number of subjects: 0
Study 26950204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of TA-65 (250 U)
Number of subjects: 117
Study 26950204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26950204 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of TA-65 (1000 U)
Number of subjects: 117
Study 1449041 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of levothyroxine
Number of subjects: 30
Study 1449041 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of iodide
Number of subjects: 30
Study 1449041 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of iodide plus 50 micrograms of levothyroxine
Number of subjects: 30
Study 1449041 — intervention group
Group type: COMPARATOR
Intervention: levothyroxine
Number of subjects: 30
Study 22864277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 6 months
Number of subjects: 40
Study 22864277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 6 months
Number of subjects: 40
Study 20045151 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months including health monitoring, counseling, health education, exercise, and dieting.
Number of subjects: 52
Study 20045151 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program for 6 months.
Number of subjects: 52